Regeneron Pharmaceuticals, Inc (USA)

Regeneron Pharmaceuticals, Inc is an American biotechnology company founded in 1988 that invents, develops and commercializes medicines for serious diseases. It is led by physician-scientists and run on an internal research model: almost all of its approved treatments and product candidates in development were discovered in its own laboratories rather than in-licensed from elsewhere. The company employs more than 15,000 people, among them over 1,400 holding MDs and/or PhDs, and operates through a global network of teams.

Its scientific work spans antibody discovery and fully human antibody engineering, bispecific antibody development, genetics and genomics, genetic medicine platforms and data-powered scientific insights. Two proprietary assets anchor the effort. VelociSuite® is a set of antibody discovery technologies that produces optimised fully human antibodies and new classes of bispecific antibodies. The Regeneron Genetics Center® (RGC) is a genetics research centre that turns large-scale genomic data into insights intended to guide future medicine.

The company's therapeutic reach is broad, covering ophthalmology, allergy and inflammation, oncology, cardiovascular and metabolic diseases, neurology, hematology, infectious diseases and rare diseases. Over more than 35 years of operation it has brought numerous treatments to market and maintains a pipeline of candidates in development, spanning drug discovery, biologics manufacturing and commercialisation.